Programme : Back to Kate Feeney

Rational design of dual kinase-bromodomain inhibitors for therapeutic polypharmacology


We recently reported that several clinical kinase inhibitors also inhibit bromodomain epigenetic reader proteins with therapeutically relevant potencies (Nat. Chem. Biol. (2014) doi: 10.1038/nchembio.1471). Nanomolar activity on BRD4 by BI-2536 and TG-101348, clinical PLK1 and JAK2/FLT3 kinase inhibitors, respectively, was particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a novel strategy for rational single agent polypharmacological targeting. Furthermore, structure-activity relationships and co-crystal structures identified design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors. Here we present data from the DiscoveRx KINOMEscan and BROMOscan platforms that demonstrate feasibility for the rational design of dual inhibitors that target new kinase-bromodomain pairs. These results suggest that the concept of dual kinase-bromo-domain inhibitors can be expanded beyond PLK, JAK2, and FLT3 kinases and beyond BET family bromodomains as well.
Add to favourites

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
iPhone App
Android App
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2018